NVSEF News and Press, Novartis Ag Basel Akt From 02/16/23

Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...

Summary Novo Nordisk is a market leader and the only pure-play in the diabetes and obesity care space. The nature of the diabetes care business makes Novo Nordisk rather recession-proof. The stock priced in much of the assumed future growth and I have concerns about competition, esp...

Summary POINT Biopharma Global Inc. has a set of radioligand therapies in various stages. It has a major deal with Lantheus. The company has a long cash runway. POINT Biopharma Global Inc. ( PNT ) is a clinical-stage company developing radioligands targeting cancer. It...

Summary It's a challenging time for biotechs needing cash. Sana Biotechnology is such a company from the stable of Boston-based Flagship Pioneering. Sana was launched to pioneer a particular aspect of DNA-based therapies. This is new and revolutionary and likely to take time to matu...

Summary Erasca, Inc. is a clinical-stage biopharmaceutical developer of therapies for patients with RAS/MAPK pathway-driven cancers. Shares were dragged down sharply by headwinds from the Fed's hawkish stance and other macroeconomic issues. Erasca has some positive catalysts that co...

Summary Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. The company's total revenue was $2,508.5 million in the third quarter of 2022, down 9.7% from the previous year. The decline ...

Novartis ( NYSE: NVS ) ( OTCPK:NVSEF ) has halted its development program for Huntington’s disease (HD) candidate branaplam after an analysis of mid-stage data, the Swiss pharma giant said Wednesday with its Q4 2022 results. The company attributed the decision to a benefit-...

Summary After a year of churn and doldrums, TG Therapeutics, Inc. finally got approval for, and launched, briumvi or ublituximab in RRMS. I am trying to decide what to do with my TG Therapeutics shares, now that I have just broken even after doubling down twice. I think I will hold ...

Novartis AG (NVS) Q4 2022 Earnings Conference Call February 01, 2023 08:00 AM ET Company Participants Samir Shah - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants ...

Summary Novartis reported Q4 results that missed the consensus revenue estimate. The underlying performance was good, however, as currency-neutral revenue and profit grew. The outlook for 2023 is positive, and the company offers nice shareholder returns. Article Thesis ...